{"id":40046,"date":"2022-01-24T21:09:44","date_gmt":"2022-01-25T03:09:44","guid":{"rendered":"https:\/\/federal-lawyer.com\/?page_id=40046"},"modified":"2025-02-22T04:48:21","modified_gmt":"2025-02-22T10:48:21","slug":"defense-strategies-for-labs-facing-an-fbi-or-oig-investigation","status":"publish","type":"page","link":"https:\/\/federal-lawyer.com\/healthcare-defense\/fbi-oig-investigation-lab-defense\/","title":{"rendered":"Lab Defense Attorneys for Executives"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">FBI or OIG Investigation? We Can Help. <\/h2>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image aligncenter size-full is-resized\">\n\t<a href=\"https:\/\/federal-lawyer.com\/healthcare-defense\/lynette-byrd\/\"><img decoding=\"async\" src=\"https:\/\/federal-lawyer.com\/wp-content\/uploads\/2024\/06\/Byrd_Lynette_400x600-280x420.jpg\" alt=\"Lynette Byrd\" class=\"wp-image-398 contact-img\" style=\"width:200px;height:300px\" width=\"200\" height=\"300\" srcset=\"https:\/\/federal-lawyer.com\/wp-content\/uploads\/2024\/06\/Byrd_Lynette_400x600-280x420.jpg 280w, https:\/\/federal-lawyer.com\/wp-content\/uploads\/2024\/06\/Byrd_Lynette_400x600-200x300.jpg 200w, https:\/\/federal-lawyer.com\/wp-content\/uploads\/2024\/06\/Byrd_Lynette_400x600.jpg 400w\" sizes=\"(max-width: 200px) 100vw, 200px\" \/><\/a>\n\t\t\t<div style=\"font-size:.7em;\">\n\t\t<figcaption class=\"wp-element-caption\"><a href=\"https:\/\/federal-lawyer.com\/healthcare-defense\/lynette-byrd\/\"><strong>Attorney Lynette Byrd<\/strong><\/a><br>Lab Defense Attorneys Team Lead<br>Former DOJ Attorney<!-- \n<a href=\"https:\/\/federal-lawyer.com\/healthcare-defense\/contact-lynette\/\" class=\"contact-link-inner\"><img decoding=\"async\" src=\"https:\/\/federal-lawyer.com\/wp-content\/uploads\/2023\/07\/circled-envelope-1.png\" alt=\"envelope icon\" class=\"wp-image-59478\"\/>Contact Lynette<\/a> -->\n\t\t<\/div>\n\t\t\t<\/figcaption>\n<\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image aligncenter size-full\">\n\t<a href=\"https:\/\/federal-lawyer.com\/healthcare-defense\/dr-nick-oberheiden\/\"><img decoding=\"async\" class=\"wp-image-22455 contact-img\" style=\"width: 200px;\" src=\"https:\/\/federal-lawyer.com\/wp-content\/uploads\/2019\/03\/dr-nick-oberheiden-attorney-at-law.jpg\" alt=\"Nick Oberheiden\" \/><\/a>\n\t\t<div style=\"font-size:.7em;\">\n\t\t\t<figcaption class=\"wp-element-caption\"><a href=\"https:\/\/federal-lawyer.com\/healthcare-defense\/dr-nick-oberheiden\/\"><strong>Attorney Nick Oberheiden<\/strong><\/a><br>Lab Defense Attorneys Team Lead<!-- \n\t\t\t\t<a href=\"https:\/\/federal-lawyer.com\/contact-nick\/\" class=\"contact-link-inner\"><img decoding=\"async\" src=\"https:\/\/federal-lawyer.com\/wp-content\/uploads\/2023\/07\/circled-envelope-1.png\" alt=\"envelope icon\" class=\"wp-image-59478\"\/>Contact Nick<\/a> -->\n\t\t<\/div>\n\t\t\t<\/figcaption>\n<\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><a href=\"https:\/\/federal-lawyer.com\/healthcare-defense\/wade-a-mcfaul\/\"><img decoding=\"async\" src=\"https:\/\/federal-lawyer.com\/wp-content\/uploads\/2020\/02\/Mcfaul-200x300-1.png\" alt=\"Wade McFaul\" class=\"wp-image-23230 contact-img\" style=\"width:200px;height:300px\" width=\"200\" height=\"300\"\/><\/a><figcaption class=\"wp-element-caption\"><a href=\"https:\/\/federal-lawyer.com\/healthcare-defense\/wade-a-mcfaul\/\"><strong>Wade McFaul<\/strong><\/a><br>Lab Defense Attorneys Consultant<br>Former HHS-OIG Assistant Special Agent-in-Charge<\/figcaption><\/figure>\n<\/div><\/div>\n<\/div>\n\n\n\n<p>The United States Health and Human Services Office of Inspector General (HHS OIG) and the Federal Bureau of Investigation has recently illustrated a renewed interest in investigating and prosecuting clinical laboratories. While it seemed as though many labs were given a \u201cfree pass\u201d during the <a href=\"https:\/\/federal-lawyer.com\/criminal-law\/lab-fraud-covid-19\/\">COVID-19<\/a> pandemic, that time appears to be up. Recently, the federal government has announced dozens of prosecutions involving molecular and respiratory labs; many of these cases relate to how these labs handle COVID-related issues.<\/p>\n\n\n\n<p>Once the OIG or FBI gets their foot in the door, their investigation is not limited to COVID-related procedures; they will often conduct a lab-wide investigation looking for any sign of misconduct. And given the complexity of the regulatory environment labs face, even well-intentioned labs may find themselves in violation of the <a href=\"https:\/\/federal-lawyer.com\/healthcare-defense\/\">federal healthcare fraud<\/a> laws. Thus, after the announcement of an upcoming federal investigation, everything must be done to ensure a favorable outcome.<\/p>\n\n\n\n\n\n<p><strong>Matters we handle on behalf of independent and physician-owned laboratories include (but are not limited to) those involving:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Clinical research contract and other contract disputes<\/li>\n\n\n\n<li>Clinical Laboratory Improvement Amendments (CLIA) violations<\/li>\n\n\n\n<li>False Claims Act (FCA) violations<\/li>\n\n\n\n<li>Health Insurance Portability and Accountability Act (HIPAA) violations<\/li>\n\n\n\n<li>Licensing violations<\/li>\n\n\n\n<li>Marketing and labeling violations<\/li>\n\n\n\n<li>Medicare, Medicaid, Tricare, and U.S. Department of Labor (DOL) billing violations<\/li>\n\n\n\n<li>MAC, RAC, UPIC, and ZPIC audits<\/li>\n\n\n\n<li>Stark Law and Anti-Kickback Statute violations<\/li>\n\n\n\n<li>U.S. Food and Drug Administration (FDA) defense<\/li>\n\n\n\n<li>U.S. Department of Health and Human Services\u2019 Office of Inspector General (OIG) defense<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Relevant Laboratory Defense &amp; Compliance Experience<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Lab Compliance Counseling<\/h3>\n\n\n\n<p>Our firm represents independent and physician-owned laboratories throughout the country as compliance counsel. Our attorneys draft custom-tailored compliance policies and procedures, assist with compliance training and implementation, and conduct compliance audits for our clients. Our lab compliance programs are comprehensive, and are designed specifically to help our clients withstand scrutiny during federal audits and investigations.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Lab Audit Defense<\/h3>\n\n\n\n<p>We have successfully represented numerous independent and physician-owned laboratories in MAC, RAC, UPIC, and ZPIC audits. These audits present unique challenges, and achieving a favorable outcome is as much about ensuring that auditors follow the rules as it is about demonstrating compliance. We have successfully defended labs during private insurance audits as well, in many cases correcting auditors\u2019 mistakes and protecting our clients against substantial unwarranted liability.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Federal Investigations<\/h3>\n\n\n\n<p>Federal investigations can present significant risks for independent and physician-owned laboratories. Without a strategic defense, labs and their owners can face substantial liability, loss of program eligibility, and even prison time. Our lawyers have handled hundreds of investigations involving all major federal law enforcement agencies, and we have resolved the majority of our clients\u2019 investigations without charges being filed.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">FDA and OIG Defense<\/h3>\n\n\n\n<p>The FDA and OIG aggressively enforce labs\u2019 compliance obligations. If your lab is facing FDA or OIG scrutiny, it is important that you engage defense counsel promptly. We have significant experience representing labs in FDA and OIG matters, and we have been successful in helping most of our laboratory clients avoid any civil or criminal liability.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Private Litigation<\/h3>\n\n\n\n<p>We also have experience representing independent and physician-owned laboratories in private litigation and other dispute resolution proceedings. This includes matters involving private insurance carriers and other commercial parties.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How Labs Can Defend Themselves in the Face of an FBI\/OIG Investigation<\/h2>\n\n\n\n<p>If you recently learned that your lab is under investigation by the FBI or OIG, there are steps you can take to protect yourself from civil and criminal liability. While the best life of defense against a federal investigation into your lab is to develop a robust compliance program, at the moment an investigation is opened, your efforts should shift away from compliance and onto damage control. This isn\u2019t to say that a late-in-the-game compliance strategy is worthless; that\u2019s not the case at all. However, while developing a compliance strategy to address any deficits will help mitigate liability, it may not be enough, and other efforts must be made.<\/p>\n\n\n\n<p>That said, below are a few things to keep in mind if you recently learned that your lab is under investigation by the FBI or OIG.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Retain All Records (Especially Those You Don\u2019t Want To)<\/h3>\n\n\n\n<p>The moment that the Department of Justice of OIG announces an investigation, you assume an immediate duty to preserve any evidence that relates to the government\u2019s investigation. Thus, anything you do to hide, alter or destroy evidence will very likely come back to bite you. For example, if the federal government learns that you destroyed or altered evidence, it could lead to an adverse inference allowing the judge or jury to assume that the evidence, if presented, would have been harmful to your case. It can also result in new criminal charges for the destruction of evidence or interfering with a federal investigation. Thus, despite any temptations, refrain from doing anything to hinder the investigation.<\/p>\n\n\n\n<p>Evidence that investigators may want to review includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Billing records;<\/li>\n\n\n\n<li>Documentation of medical necessity;<\/li>\n\n\n\n<li>Documentation of any referral relationships with doctors, pharmacies, hospitals, marketers or consultants; and<\/li>\n\n\n\n<li>The lab\u2019s OIG compliance program.<\/li>\n<\/ul>\n\n\n\n<p>Of course, this is a partial list, and federal agents may seek a broad range of evidence during the course of their investigation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Be Prepared<\/h3>\n\n\n\n<p>When FBI or OIG agents arrive to conduct an investigation, a clinical or molecular lab should be expecting their arrival and have taken the necessary steps to prepare for the investigation. This includes making all records that the investigators will likely want to examine easily accessible. The last thing you want is for agents to be rifling around your lab any more than absolutely necessary. You also do not want to appear unorganized, as agents may take your lack of organization as an indication that you play fast and loose with the rules.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Don\u2019t Talk to Federal Agents Any More Than Necessary<\/h3>\n\n\n\n<p>If the FBI or OIG comes to your lab to conduct an investigation, they are naturally going to ask you questions. However, you are under absolutely no duty to answer them. Not only that, but answering federal agents\u2019 questions can only hurt you. For example, if you say something you think is helping you, will the agents believe you? Probably not without documentation that supports what you told them. On the other hand, if you say something against your interest, they will certainly believe you. The result is that there is no reason to talk to FBI or OIG investigators if they ask questions during an investigation. The better option is to retain an experienced federal defense lab lawyer who can interact with law enforcement on your behalf.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Be Careful Who Else You Talk To<\/h3>\n\n\n\n<p>An FBI or OIG investigation is not necessarily limited to what is within the walls of your lab. Investigators may ask affiliated third parties for evidence or testimony. Thus, once you are made aware of an investigation, it is important not to talk with these parties about the investigation. Innocent words can be taken out of context, and you can\u2019t be sure who is going to end up working with federal agents. Often, agents will try to \u201cflip\u201d certain participants, providing them with immunity or a favorable plea agreement in exchange for their testimony against other participants. You don\u2019t want to be on the wrong end of that deal.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Reach Out to an Experienced Lab Defense Lawyer with Experience Defending Independent Clinical Laboratories and Physician Owned Laboratories (POLs)<\/h3>\n\n\n\n<p>If you are under investigation by the FBI or OIG, chances are this is the first time. That being the case, you may not know what to expect or how to best protect your interests. By retaining an experienced <a href=\"https:\/\/federal-lawyer.com\/team\/\">clinical lab defense law firm<\/a>, you will benefit from their experience. Whether it\u2019s helping you identify the potential areas of compliance concern, negotiating with the DOJ after an unfavorable investigation, or litigating civil or criminal charges at trial, an attorney\u2019s assistance is an invaluable asset to molecular and respiratory labs subject to a federal investigation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Lab Defense Focus Areas<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/federal-lawyer.com\/healthcare-defense\/defending-anti-kickback-charges\/\">Anti-Kickback Statute<\/a> and <a href=\"https:\/\/federal-lawyer.com\/healthcare\/healthcare-compliance\/stark-law\/\">Stark Law Defense<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/federal-lawyer.com\/how-cgx-laboratories-can-be-compliant\/\">CGX Compliance and Defense<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/federal-lawyer.com\/lab-fraud-alert-healthcare-fraud-related-to-covid-19-testing\/\">COVID-19 Testing Fraud<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/federal-lawyer.com\/healthcare-defense\/fda-fraud-investigations\/\">FDA Fraud Investigations<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/federal-lawyer.com\/healthcare-compliance\/laboratory-billing\/\">Laboratory Billing Compliance<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/federal-lawyer.com\/healthcare\/healthcare-compliance\/oig-compliance\/clinical-laboratories\/\">OIG Compliance<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/federal-lawyer.com\/healthcare\/healthcare-compliance\/toxicology-clinical-laboratory\/\">OIG Fraud Investigations<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/federal-lawyer.com\/defending-toxicology-labs-false-claims-act-cases\/\">Toxicology Laboratory Defense<\/a><\/li>\n\n\n\n<li>And more! <\/li>\n<\/ul>\n\n\n\n<div class=\"iframe-container\">\n<iframe src=\"https:\/\/www.youtube.com\/embed\/7-ODeKIpoYs\" title=\"YouTube video player\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen=\"\" width=\"1000\" height=\"500\" frameborder=\"0\"><\/iframe>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\">FAQs: FBI and OIG Investigations Targeting Labs and Their CEOs<\/h2>\n\n\n\n<div class=\"faqs\">\n\n\t<div class=\"faq_inner\">\n        <div class=\"toggle\">\n\t\t\t<h3 class=\"faq_que\">Which Federal Agencies Regulate Laboratories?<\/h3>\n\t\t\t<div class=\"faq_icon\">&nbsp;<\/div>\n\t\t<\/div>\n\t\t<div class=\"faq_ans\">\n\t\t\t<p>Many lab owners and executives are surprised to learn just how many federal agencies have oversight and regulatory authority over their laboratories. All lab owners and executives should be familiar with the U.S. Food and Drug Administration\u2019s (FDA) role in regulating laboratories in the United States, and most will be well aware of the U.S. Centers for Medicare and Medicaid Services\u2019 (CMS) role in ensuring compliance. But many owners and executives are surprised to learn that the Federal Bureau of Investigation (FBI), U.S. Department of Justice (DOJ), U.S. Department of Health and Human Services Office of Inspector General (OIG), and other federal authorities could be scrutinizing their business practices as well.<\/p>\n\t\t<\/div>\n\t<\/div>\n\n\t<div class=\"faq_inner\">\n        <div class=\"toggle\">\n\t\t\t<h3 class=\"faq_que\">When Can a Lab (or Lab Executive) Face Liability Under the Anti-Kickback Statute?<\/h3>\n\t\t\t<div class=\"faq_icon\">&nbsp;<\/div>\n\t\t<\/div>\n\t\t<div class=\"faq_ans\">\n\t\t\t<p>Labs and lab executives can face liability under the Anti-Kickback Statute when they engage in (or attempt to engage in) prohibited financial relationships. Broadly speaking, the Anti-Kickback Statute prohibits health care entities from paying or accepting referral fees and other forms of \u201cremuneration\u201d using funds received from federal payors (i.e., Medicare and Medicaid). It also outlaws <em>attempts<\/em> to pay or accept these forms of compensation, as it specifically includes \u201coffering\u201d and \u201csoliciting\u201d remuneration among its prohibitions.<\/p>\n\n\t\t\t<p>The regulations promulgated under the Anti-Kickback Statute establish several \u201csafe harbors,\u201d and defending against alleged Anti-Kickback Statute violations often involves proving that a safe harbor applies. But, if a lab has not specifically structured a financial relationship to satisfy a safe harbor\u2019s requirements, establishing safe harbor protection may not be possible.<\/p>\n\t\t<\/div>\n\t<\/div>\n\n\t<div class=\"faq_inner\">\n        <div class=\"toggle\">\n\t\t\t<h3 class=\"faq_que\">What Do Doctors Who Own Labs Need to Know about the Stark Law?<\/h3>\n\t\t\t<div class=\"faq_icon\">&nbsp;<\/div>\n\t\t<\/div>\n\t\t<div class=\"faq_ans\">\n\t\t\t<p>The Stark Law prohibits unlawful referral fees, much like the Anti-Kickback Statute. However, it applies specifically to doctors, and even <em>more<\/em> specifically to so-called physician \u201cself-referrals.\u201d For doctors who own labs, it is imperative to ensure that any financial relationships between their labs and their medical practices do not violate the Stark Law\u2019s prohibitions.<\/p>\n\t\t<\/div>\n\t<\/div>\n\n\t<div class=\"faq_inner\">\n        <div class=\"toggle\">\n\t\t\t<h3 class=\"faq_que\">What are the Consequences of Violating CLIA?<\/h3>\n\t\t\t<div class=\"faq_icon\">&nbsp;<\/div>\n\t\t<\/div>\n\t\t<div class=\"faq_ans\">\n\t\t\t<p>The Clinical Laboratory Improvement Amendments (CLIA) and the CLIA regulations establish mandatory quality standards for laboratory testing. CLIA compliance is an essential component of a broader laboratory compliance program, as failure to comply with CLIA or the CLIA regulations can have severe consequences. On top of loss of CLIA certification, labs that fail to maintain compliance can face civil monetary penalties (CMP). Since these CMP are imposed on a per-violation basis, labs that violate CLIA or the CLIA regulations can easily face hundreds of thousands of dollars\u2014if not millions of dollars\u2014in penalty liability.<\/p>\n\t\t<\/div>\n\t<\/div>\n\n\t<div class=\"faq_inner\">\n        <div class=\"toggle\">\n\t\t\t<h3 class=\"faq_que\">Can a Lab Lose Its License Due to an FBI or OIG Investigation?<\/h3>\n\t\t\t<div class=\"faq_icon\">&nbsp;<\/div>\n\t\t<\/div>\n\t\t<div class=\"faq_ans\">\n\t\t\t<p>Yes, laboratories and physician-owners can lose their licenses due to FBI and OIG investigations. The FDA and CMS can suspend laboratories\u2019 licenses (i.e., FDA registration and CLIA certification), and state medical boards can suspend or revoke physicians\u2019 medical licenses if they are found in violation of pertinent federal laws. This is yet another reason why labs that are facing FBI and OIG investigations need to engage experienced defense counsel promptly.<\/p>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n<br>\n\n\n\n\n<h2 class=\"wp-block-heading\">The Lab Attorneys at Oberheiden, P.C. Represents Labs &amp; CEOs Under Federal Investigation<\/h2>\n\n\n\n<p>If your respiratory or molecular lab is under investigation by the OIG or FBI, reach out to <a href=\"https:\/\/federal-lawyer.com\/\">Oberheiden, P.C.<\/a> as soon as possible. We have attorneys standing by to answer your questions and immediately get involved in your case. Many of our senior lab defense attorneys were formerly employed in high-ranking positions with the federal government and command an in-depth knowledge of how these investigations are handled. We are prepared to put this knowledge to use, protecting you and your lab. To learn more, and to schedule case evaluation with a clinical lab defense lawyer, give Oberheiden, P.C. a call at 888-680-1745 or fill out our <a href=\"https:\/\/federal-lawyer.com\/healthcare-defense\/contact\/\" rel=\"nofollow\">online form<\/a>.<\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>FBI or OIG Investigation? We Can Help. Attorney Lynette ByrdLab Defense Attorneys Team LeadFormer DOJ Attorney Attorney Nick OberheidenLab Defense Attorneys Team Lead The United States Health and Human Services Office of Inspector General (HHS OIG) and the Federal Bureau of Investigation has recently illustrated a renewed interest in investigating and prosecuting clinical laboratories. While &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/federal-lawyer.com\/healthcare-defense\/fbi-oig-investigation-lab-defense\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lab Defense Attorneys for Executives&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"parent":53,"menu_order":358,"comment_status":"closed","ping_status":"closed","template":"page-templates\/healthcare-defense-child.php","meta":{"_acf_changed":false,"_mo_disable_npp":"","footnotes":""},"class_list":["post-40046","page","type-page","status-publish","hentry","entry"],"acf":[],"distributor_meta":false,"distributor_terms":false,"distributor_media":false,"distributor_original_site_name":"Federal Lawyer","distributor_original_site_url":"https:\/\/federal-lawyer.com","push-errors":false,"_links":{"self":[{"href":"https:\/\/federal-lawyer.com\/wp-json\/wp\/v2\/pages\/40046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/federal-lawyer.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/federal-lawyer.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/federal-lawyer.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/federal-lawyer.com\/wp-json\/wp\/v2\/comments?post=40046"}],"version-history":[{"count":7,"href":"https:\/\/federal-lawyer.com\/wp-json\/wp\/v2\/pages\/40046\/revisions"}],"predecessor-version":[{"id":100664,"href":"https:\/\/federal-lawyer.com\/wp-json\/wp\/v2\/pages\/40046\/revisions\/100664"}],"up":[{"embeddable":true,"href":"https:\/\/federal-lawyer.com\/wp-json\/wp\/v2\/pages\/53"}],"wp:attachment":[{"href":"https:\/\/federal-lawyer.com\/wp-json\/wp\/v2\/media?parent=40046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}